En placebokontrolleret undersogelse
Orskov C, Wettergren A, and Holst JJ
Maier et al, 2021), enabling comparative analysis
CKD affects 20%-55% of MASLD patients and shares pathogenic mechanisms with MASLD through insulin resistance, oxidative stress, and systemic inflammation [15]
doi: 10.1371/journal.pgph.0005516
Obesity is considered a chronic condition and GLP-1 medications are intended for long-term use Evidence shows that stopping the medication often leads to weight regain Many patients remain on therapy indefinitely, similar to treatments for other chronic conditions (e.g., hypertension or diabetes), provided the medication is effective and well tolerated Periodic reassessment ensures the treatment remains appropriate and beneficial GLP-1 Agonists: A Powerful Tool for Sustainable Weight Management One of the most exciting advancements Ive seen in clinical practice is the use of GLP-1 receptor agonists medications that are transforming how we approach obesity and metabolic health